Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irradiated Haploidentical Cells for AML Remission
NCT02105116Terminated
- Sponsor
- Rutgers University
- Start
- Feb 2014
- Primary completion
- Dec 2015
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Open-label, single-arm trial of donor lymphocytes in acute myeloid leukemia (AML), sponsored by Rutgers University. Primary endpoints: Toxicity of haploidentical allogeneic cellular therapy up to 2 years, Efficacy of haploidentical allogeneic cellular therapy (remission rates) at 24 months and 2 more. Started Feb 2014; status: terminated.
02
Drugs
donor lymphocytes
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02105116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02105116.